Posted by Michael Wonder on 29 Jul 2017
European Commission grants AbbVie's Maviret (glecaprevir/pibrentasvir) marketing authorisation for the treatment of chronic hepatitis C in all major genotypes (GT1-6)
28 July 2017 - AbbVie's investigational, pan-genotypic HCV treatment is also under priority review by the U.S. FDA.
AbbVie today announced that the European Commission has granted marketing authorization for Maviret (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). Maviret is a new 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment,* who comprise the majority of the 71 million people living with HCV globally.
The approval of Maviret is supported by data from eight registrational studies in AbbVie's clinical development program, which evaluated more than 2,300 patients in 27 countries across all major HCV genotypes (GT1-6) and special populations.
